
The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.
Darzalex Faspro is the first and only approved treatment for high-risk smoldering multiple myeloma (HR-SMM), enabling earlier intervention before the disease progresses to active multiple myeloma.